Permanently extends the HHS Secretary's authority to award priority review vouchers for rare pediatric disease products.
The bill amends the Federal Food, Drug, and Cosmetic Act to permanently extend the authority of the Secretary of Health and Human Services to award priority review vouchers for rare pediatric disease products. This change ensures that the HHS Secretary can continue to prioritize the review of drugs and treatments for rare pediatric diseases, potentially speeding up their approval and availability.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.